FI117851B - Nestemäinen oftalminen pitkävaikutteinen vapautusjärjestelmä - Google Patents

Nestemäinen oftalminen pitkävaikutteinen vapautusjärjestelmä Download PDF

Info

Publication number
FI117851B
FI117851B FI963217A FI963217A FI117851B FI 117851 B FI117851 B FI 117851B FI 963217 A FI963217 A FI 963217A FI 963217 A FI963217 A FI 963217A FI 117851 B FI117851 B FI 117851B
Authority
FI
Finland
Prior art keywords
ophthalmic
agent
chitosan
eye
release system
Prior art date
Application number
FI963217A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963217A0 (fi
FI963217A (fi
Inventor
Shau-Fong Yen
Kenneth W Reed
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FI963217A0 publication Critical patent/FI963217A0/fi
Publication of FI963217A publication Critical patent/FI963217A/fi
Application granted granted Critical
Publication of FI117851B publication Critical patent/FI117851B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
FI963217A 1994-02-18 1996-08-16 Nestemäinen oftalminen pitkävaikutteinen vapautusjärjestelmä FI117851B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/198,924 US5422116A (en) 1994-02-18 1994-02-18 Liquid ophthalmic sustained release delivery system
US19892494 1994-02-18
PCT/IB1995/000082 WO1995022315A1 (en) 1994-02-18 1995-02-09 Liquid ophthalmic sustained release delivery system
IB9500082 1995-02-09

Publications (3)

Publication Number Publication Date
FI963217A0 FI963217A0 (fi) 1996-08-16
FI963217A FI963217A (fi) 1996-08-16
FI117851B true FI117851B (fi) 2007-03-30

Family

ID=22735469

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963217A FI117851B (fi) 1994-02-18 1996-08-16 Nestemäinen oftalminen pitkävaikutteinen vapautusjärjestelmä

Country Status (21)

Country Link
US (1) US5422116A (pt)
EP (1) EP0744938B1 (pt)
JP (1) JP3720359B2 (pt)
CN (1) CN1138530C (pt)
AT (1) ATE205079T1 (pt)
AU (1) AU704353B2 (pt)
CA (1) CA2181715C (pt)
CY (1) CY2314B1 (pt)
DE (1) DE69522550T2 (pt)
DK (1) DK0744938T3 (pt)
ES (1) ES2163495T3 (pt)
FI (1) FI117851B (pt)
GR (1) GR3036884T3 (pt)
IL (1) IL112674A (pt)
MX (1) MX9603435A (pt)
NO (1) NO313861B1 (pt)
NZ (1) NZ278668A (pt)
PT (1) PT744938E (pt)
TW (1) TW317501B (pt)
WO (1) WO1995022315A1 (pt)
ZA (1) ZA951323B (pt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762903A (en) * 1995-03-10 1998-06-09 Korea Atomic Energy Research Institute Radioactive chitosan complex for radiation therapy
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
PT782448E (pt) * 1995-06-06 2002-07-31 Bayer Ag Formulacoes oticas antibacterianas nao ototoxicas nao sensibilizantes nao irritantes
AU6742696A (en) * 1995-08-17 1997-03-12 Ciba-Geigy Ag Stabilized chitin derivative compounds
TW389694B (en) * 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
ES2320579T3 (es) * 1998-05-08 2009-05-25 The University Of Miami Uso de tetraciclinas sub-antimicrobianas para tratar rosacea ocular.
US7288532B1 (en) * 1998-08-21 2007-10-30 The University Of Maryland Biotechnology Institute Modified chitosan polymers and enzymatic methods for the production thereof
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
DK1128809T3 (da) * 1998-11-20 2005-04-25 Medidom Lab Vandige oftalmiske formuleringer omfattende chitosan
TR200200737T2 (tr) * 1999-09-24 2002-08-21 Alcon, Inc. Siproflaksasin ve deksametazon içeren lokal süspansiyon formülasyonları
CA2386822A1 (en) 1999-11-01 2001-05-10 Alcon, Inc. Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
AU1375301A (en) * 1999-11-15 2001-05-30 Bio Syntech Canada Inc Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution
KR100371092B1 (ko) * 1999-12-09 2003-02-05 주식회사대성미생물연구소 동물용 복합항균제 조성물
US20030158302A1 (en) * 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
EP1255576B1 (en) * 1999-12-09 2003-08-20 Biosyntech Canada Inc. Mineral-polymer hybrid composition
US6348508B1 (en) * 2000-04-04 2002-02-19 Bausch & Lomb Incorporated Method for treating dry eye
US6716970B2 (en) * 2000-04-21 2004-04-06 Adjuvant Pharmaceuticals, Llc Water soluble, randomly substituted partial N-partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof
ATE238767T1 (de) * 2000-05-26 2003-05-15 Medidom Lab Antibakterielle wässerige ophtalmische formulierungen mit ofloxacin und chitosan
DK1294414T3 (da) * 2000-06-29 2006-07-24 Biosyntech Canada Inc Præparat og fremgangsmåde til heling og regenerering af brusk og andre væv
ES2225573T3 (es) 2000-07-28 2005-03-16 Alcon, Inc Composiciones farmaceuticas que contienen tobramicina y goma xantana.
DE60125973D1 (de) * 2000-11-15 2007-02-22 Biosyntech Canada Inc Verfahren zur wiederherstellung einer geschädigten bandscheibe
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
WO2003002066A2 (en) * 2001-06-27 2003-01-09 Diversa Corporation Glycosylated kinamycins and methods of making and using them
ATA13842001A (de) 2001-08-31 2002-10-15 Mucobiomer Biotechnologische F Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung
ES2353116T3 (es) * 2002-07-16 2011-02-25 Bio Syntech Canada Inc. Composiciones para disoluciones de quitosano citocompatibles, inyectables, autogelificantes para encapsular y administrar células vivas o factores biológicamente activos.
WO2004018741A1 (en) * 2002-08-23 2004-03-04 University Of Maryland Biotechnology Institute Assembly of chitosan onto an electrode surface
US7138373B2 (en) * 2002-09-26 2006-11-21 University Of Maryland, Baltimore County Polysaccharide-based polymers and methods of making the same
US7790010B2 (en) * 2002-12-20 2010-09-07 University Of Maryland, College Park Spatially selective deposition of polysaccharide layer onto patterned template
TW200416046A (en) * 2002-12-23 2004-09-01 Alcon Inc Contact lens care compositions containing chitin derivatives
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
WO2004066980A2 (en) * 2003-01-24 2004-08-12 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US7883615B2 (en) * 2003-02-12 2011-02-08 University Of Maryland, College Park Controlled electrochemical deposition of polysaccharide films and hydrogels, and materials formed therefrom
CA2516429A1 (en) * 2003-02-21 2004-10-14 Sun Pharmaceutical Industries Limited Stable ophthalmic formulation containing an antibiotic and a corticosteroid
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US7125967B2 (en) * 2003-10-08 2006-10-24 Adjuvant Pharmaceuticals, Llc Water-soluble chitosan having low endotoxin concentration and methods for making and using the same
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US7375404B2 (en) * 2003-12-05 2008-05-20 University Of Maryland Biotechnology Institute Fabrication and integration of polymeric bioMEMS
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
KR101080056B1 (ko) * 2004-12-01 2011-11-04 한국원자력연구원 체내 주사시 겔화 안정성이 개선된 방사성물질-키토산복합체용액 조성물 및 그 제조 방법
DE602005007319D1 (de) * 2005-02-17 2008-07-17 Jordanian Pharmaceutical Mfg Zubereitung zur kontinuierlichen Arzneimittelfreisetzung Chitosan enthaltend
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
CA2628244A1 (en) * 2005-11-04 2007-05-10 Bio Syntech Canada Inc. Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
US20070154523A1 (en) * 2005-12-30 2007-07-05 Rick Lewis Controlled pupil dilation for diagnostic and treatment of visual anomalies
US7785624B2 (en) * 2006-03-02 2010-08-31 Inspire Pharmaceuticals, Inc. Pharmaceutical latrunculin formulations
EP1938839B1 (en) * 2006-12-18 2009-08-19 Jorge Luis Benozzi Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia
CA2676919C (en) 2007-01-31 2013-01-29 Allergan, Inc. Novel biomaterials for ocular drug delivery and a method for making and using same
EP2134355A4 (en) * 2007-03-02 2012-01-11 Saint Simeon Lda NOVEL OPHTHALMIC COMPOSITIONS CONTAINING RECOMBINANT HUMAN LYSOZYME AND USE THEREOF FOR TREATING DISORDERS THEREOF AND SOLUTION FOR CONTACT LENSES
US8003621B2 (en) 2007-09-14 2011-08-23 Nitto Denko Corporation Drug carriers
CN101780105B (zh) * 2009-01-20 2011-09-28 沈阳兴齐制药有限公司 小牛血去蛋白提取物的滴眼液
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2011018800A2 (en) 2009-08-13 2011-02-17 Fdc Limited A novel in-situ gel forming solution for ocular drug delivery
DE102010009475B4 (de) 2010-02-26 2011-11-24 F. Holzer Gmbh Verfahren zur Herstellung eines dosierbaren applikationsfertigen Präparates
US20120231072A1 (en) * 2011-03-11 2012-09-13 Chemisches Institut Schaefer Ag Thermo-responsive hydrogel compositions
CN104093404B (zh) 2011-09-20 2016-12-07 阿勒根公司 用于治疗老花眼、轻度远视和不规则散光的组合物和方法
CN104768533A (zh) * 2012-06-11 2015-07-08 马库克利尔公司 治疗性制剂和治疗方法
WO2015055301A1 (en) * 2013-10-15 2015-04-23 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
TWI609701B (zh) * 2016-01-05 2018-01-01 國立交通大學 滴點式複合藥物凝膠及其製備方法
BR112019002967A2 (pt) 2016-08-19 2019-05-14 Orasis Pharmaceuticals Ltd. composição farmacêutica oftálmica, métodos de corrigir presbiopia, de reduzir o tamanho de uma pupila, de induzir miose, de aumentar a profundidade de campo, de diminuir a grandeza de aberrações de ordem superior e de melhorar a acuidade visual não corrigida de perto e de longe, implante, e, kit.
CN106511268A (zh) * 2017-01-22 2017-03-22 吉林省始祖生物波医学研究院有限公司 治疗眼病的溶液及其应用、眼贴及其制作方法
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
WO2019168023A1 (ja) * 2018-02-28 2019-09-06 参天製薬株式会社 ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物
WO2019193513A1 (en) * 2018-04-03 2019-10-10 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics
CA3074618C (en) 2018-04-24 2022-08-02 Allergan, Inc. Presbyopia treatments
US11344507B2 (en) 2019-01-08 2022-05-31 Alumend, Llc Topical compositions containing low molecular weight chitosan derivatives
IT201900006104A1 (it) 2019-04-18 2020-10-18 S I I T S R L Servizio Int Imballaggi Termosaldanti Metodo di preparazione di un prodotto a base di chitosano
CN111848830A (zh) * 2019-04-30 2020-10-30 苏州大学 含氟化合物修饰的壳聚糖作为药物载体的用途及其制备方法
KR102656181B1 (ko) * 2019-08-27 2024-04-08 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
CN114073670B (zh) * 2020-08-11 2023-02-24 武汉科福新药有限责任公司 马来酸噻吗洛尔凝胶滴眼液及其制备方法
AU2022212108A1 (en) * 2021-01-28 2023-08-17 Glaukos Corporation Formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4659700A (en) * 1984-03-02 1987-04-21 Johnson & Johnson Products, Inc. Chitosan-glycerol-water gel
EP0244178A3 (en) * 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
IT1190347B (it) * 1986-06-16 1988-02-16 Franco Conti Processo per la preparazione dell'n-dimetilchitosano e suoi impieghi farmacologici
JPS6471822A (en) * 1987-09-12 1989-03-16 Rohto Pharma Ophthalmic sustained release preparation
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
JPH0418022A (ja) * 1990-05-10 1992-01-22 Fujikawa Kk ピロキシカムの安定水溶液ならびにその製造法
JP2536806B2 (ja) * 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels

Also Published As

Publication number Publication date
CN1138530C (zh) 2004-02-18
FI963217A0 (fi) 1996-08-16
NO963431D0 (no) 1996-08-16
DK0744938T3 (da) 2001-12-31
CA2181715C (en) 2006-05-30
TW317501B (pt) 1997-10-11
DE69522550D1 (de) 2001-10-11
ATE205079T1 (de) 2001-09-15
AU704353B2 (en) 1999-04-22
DE69522550T2 (de) 2002-05-02
MX9603435A (es) 1997-03-29
CN1140988A (zh) 1997-01-22
ZA951323B (en) 1995-08-18
GR3036884T3 (en) 2002-01-31
IL112674A0 (en) 1995-05-26
EP0744938A1 (en) 1996-12-04
FI963217A (fi) 1996-08-16
JPH09509166A (ja) 1997-09-16
NO313861B1 (no) 2002-12-16
AU1464995A (en) 1995-09-04
IL112674A (en) 1999-12-22
JP3720359B2 (ja) 2005-11-24
ES2163495T3 (es) 2002-02-01
NZ278668A (en) 1998-01-26
EP0744938B1 (en) 2001-09-05
CY2314B1 (en) 2003-11-14
US5422116A (en) 1995-06-06
CA2181715A1 (en) 1995-08-24
WO1995022315A1 (en) 1995-08-24
PT744938E (pt) 2001-12-28
NO963431L (no) 1996-10-09

Similar Documents

Publication Publication Date Title
FI117851B (fi) Nestemäinen oftalminen pitkävaikutteinen vapautusjärjestelmä
Vandamme et al. Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide
JP2969584B2 (ja) 眼の治療用組成物
JP4545927B2 (ja) キサンタンガムを含有するゲル化眼科用組成物
US6174524B1 (en) Gelling ophthalmic compositions containing xanthan gum
CN101534794A (zh) 用于递送眼科用药物的凝胶
JP5649261B2 (ja) 高粘度点眼剤
HU223071B1 (hu) Csökkentett viszkozitású szemészeti készítmény
JPH11510497A (ja) Ｏ−カルボキシアルキルキトサンを含む配合物及び眼科領域での使用方法
HU223070B1 (hu) Ionérzékeny, hidrofil polimert és szervetlen sót viszkozitáscsökkenést eredményező arányban tartalmazó szemészeti készítmény
CN101977630B (zh) 眼药组合物
US20100069323A1 (en) Composition for application to skin or mucosa
CA2193149C (en) Cationic therapuetic agents and delivery systems
US20030031718A1 (en) Ophthalmic compositions and use
AU2004305539B2 (en) Ophthalmic compositions containing a polysaccharide/borate gelling system
CN101765612A (zh) 前列腺素衍生物和单取代的带电β-环糊精的络合物
JP2014167034A (ja) 高粘度点眼剤
EP0888770A1 (en) Compositions comprising cationic polysaccharides and cationic drugs
JPH10182498A (ja) カチオン治療方式
Hazari et al. FORMULATION DEVELOPMENT AND EVALUATION OF IN SITU NASAL DRUG DELIVERY SYSTEM OF POORLY WATER SOLUBLE DRUGS UTILIZING MIXED SOLVENCY CONCEPT
SANGEETHA FORMULATION AND EVALUATION OF NIOSOMAL IN SITU GEL OCULAR DELIVERY SYSTEM OF BRIMONIDINE TARTRATE V. SATHYAVATHI1, A. ABDUL HASANSATHALI*, R. ILAVARASAN2

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Ref document number: 117851

Country of ref document: FI